CD38 and B-cell chronic lymphocytic leukemia: Patients with CLL with a higher proportion of leukemic cells expressing CD38 ≥30% experience a shorter time to first treatment and a more aggressive clinical course with inferior overall survival compared to patients who have <30% of CD38+ CLL cells, thus establishing surface CD38 as a marker of poor prognosis (135–137).